Fatty Liver Treatment Market Report 2026

The fatty liver treatment market size has grown strongly in recent years. It will grow from $25.05 billion in 2025 to $26.75 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increase in obesity rates, rising diabetes prevalence, improved liver diagnostic tools, growing awareness of liver health, expansion of hepatology clinics.

The fatty liver treatment market size is expected to see strong growth in the next few years. It will grow to $35.67 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to development of novel NAFLD drugs, increased use of non-invasive diagnostics, growth in preventive healthcare, expansion of tele-hepatology services, rising investment in liver disease research. Major trends in the forecast period include rising prevalence of non-alcoholic fatty liver disease, increased focus on lifestyle-based treatment approaches, growing use of targeted drug therapies, expansion of early liver disease screening, integration of digital health for disease monitoring.

The rising alcohol consumption is expected to drive growth in the fatty liver treatment market in the coming years. Alcohol consumption refers to the intake of beverages containing alcohol, a psychoactive substance with depressant effects on the central nervous system. Excessive alcohol intake can exacerbate fatty liver disease and lead to more severe liver conditions, including alcoholic fatty liver disease (AFLD) and alcoholic hepatitis. For example, in November 2025, the OECD, a Paris-based intergovernmental organization, reported that per capita annual alcohol consumption across member countries averaged 8.5 liters of pure alcohol in 2023. Therefore, the increase in alcohol consumption is contributing to the growth of the fatty liver treatment market.

Key companies in the fatty liver treatment market are focusing on developing innovative solutions, such as next-generation metabolic-modulating biologics, to address the growing need for effective therapies targeting the underlying mechanisms of NAFLD and NASH. These biologic therapies act on critical metabolic and inflammatory pathways, providing a more targeted and disease-modifying approach compared with traditional lifestyle-based interventions, which have limited effectiveness in advanced disease. For instance, in March 2023, Akero Therapeutics, a US-based biotechnology company, reported positive Phase II results for efruxifermin, indicated for the treatment of non-invasively diagnosed nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Efruxifermin is a differentiated Fc-FGF21 fusion protein that replicates the biological activity of fibroblast growth factor 21 (FGF21), which regulates multiple metabolic pathways and cellular processes.

In March 2023, Ipsen, a France-based biopharmaceutical company, acquired Albireo Pharma Inc. for $952 million. This acquisition significantly strengthened Ipsen’s focus on rare diseases with unique pipeline potential, providing promising therapies for uncommon cholestatic liver disorders in both children and adults, as well as enhancing scientific and commercial expertise. The acquisition also expanded Ipsen’s rare disease portfolio. Albireo Pharma Inc., a US-based biotechnology company, develops bile acid modulators that can be used to treat fatty liver disorders.

Major companies operating in the fatty liver treatment market are Pfizer Inc., Johnson & Johnson Services Inc., Hoffmann La Roche Ltd., AstraZeneca plc, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., The Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Intercept Pharmaceuticals Inc., Madrigal Pharmaceuticals Inc., Genfit, Conatus Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Cardax Inc., Eisai Co. Ltd., Alnylam Pharmaceuticals Inc.

North America was the largest region in the fatty liver treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fatty liver treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fatty liver treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the fatty liver treatment market by raising prices for imported antivirals, targeted therapies, immunosuppressants, and diagnostic equipment. Hospitals and ambulatory centers in Asia-Pacific and Latin America are most impacted due to reliance on global pharmaceutical and medical device suppliers. These higher costs can restrict patient access to advanced liver treatments. However, tariffs are encouraging domestic pharmaceutical manufacturing and diagnostic services, improving long-term treatment availability.

The fatty liver treatment market research report is one of a series of new reports that provides fatty liver treatment market statistics, including fatty liver treatment industry global market size, regional shares, competitors with a fatty liver treatment market share, detailed fatty liver treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fatty liver treatment industry. This fatty liver treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fatty liver disease is a condition characterized by the accumulation of fat in the liver, leading to various symptoms and complications. Fatty liver treatment involves multiple strategies, interventions, and approaches to manage and address the disease.

The main types of fatty liver treatments include anti-rejection drugs or immunosuppressants, chemotherapy drugs, targeted therapy, vaccines, and antiviral drugs. Anti-rejection drugs, also called immunosuppressants, are medications that reduce or suppress the body’s immune response. They are indicated for conditions such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and others, and are used by hospitals, ambulatory surgery centers, and additional healthcare providers.

The fatty liver treatment market consists of revenues earned by entities by providing medical evaluation, medical diagnosis, healthcare provider consultations, nutritional guidance, medication management, ongoing monitoring, and weight management programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The fatty liver treatment market also includes sales of thiazolidinediones, vitamin E, metformin, statins, polyunsaturated fatty acids, angiotensin receptor blockers, and pentoxifylline, which are used in providing fatty liver treatment services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.